Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ARQT Arcutis Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ARQT
Price (delayed)
$13.6
Market cap
$1.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.03
Enterprise value
$1.68B
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent
Highlights
The company's revenue has surged by 100% YoY and by 8% QoQ
ARQT's gross profit has surged by 90% year-on-year and by 6% since the previous quarter
Arcutis Biotherapeutics's quick ratio has shrunk by 67% YoY and by 16% QoQ
Arcutis Biotherapeutics's equity has decreased by 37% YoY and by 9% QoQ
Key stats
What are the main financial stats of ARQT
Market
Valuations
Earnings
Shares outstanding
119.2M
Market cap
$1.62B
Enterprise value
$1.68B
Price to earnings (P/E)
N/A
Price to book (P/B)
11.31
Price to sales (P/S)
8.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.89
Revenue
$212.82M
Gross profit
$188.12M
Operating income
-$121.3M
Net income
-$129.72M
EBIT
-$106.45M
EBITDA
-$100.65M
Free cash flow
-$111.69M
Per share
Balance sheet
Liquidity
EPS
-$1.03
EPS diluted
-$1.03
Free cash flow per share
-$0.89
Book value per share
$1.2
Revenue per share
$1.69
TBVPS
$2.6
Total assets
$344.11M
Total liabilities
$201.45M
Debt
$110.8M
Equity
$142.66M
Working capital
$232.54M
Debt to equity
0.78
Current ratio
3.55
Quick ratio
3.12
Net debt/EBITDA
-0.57
Margins
Efficiency
Dividend
EBITDA margin
-47.3%
Gross margin
88.4%
Net margin
-61%
Operating margin
-57%
Return on assets
-32.9%
Return on equity
-80.7%
Return on invested capital
-29.8%
Return on capital employed
-42.1%
Return on sales
-50%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARQT stock price
How has the Arcutis Biotherapeutics stock price performed over time
Intraday
-1.59%
1 week
-0.73%
1 month
5.1%
1 year
67.28%
YTD
-2.37%
QTD
-13.04%
Financial performance
How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$212.82M
Gross profit
$188.12M
Operating income
-$121.3M
Net income
-$129.72M
Gross margin
88.4%
Net margin
-61%
The company's revenue has surged by 100% YoY and by 8% QoQ
ARQT's gross profit has surged by 90% year-on-year and by 6% since the previous quarter
Arcutis Biotherapeutics's net margin has surged by 70% YoY and by 14% QoQ
The operating margin has soared by 69% YoY and by 13% from the previous quarter
Price vs fundamentals
How does ARQT's price correlate with its fundamentals
Growth
What is Arcutis Biotherapeutics's growth rate over time
Valuation
What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
11.31
P/S
8.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.89
ARQT's EPS has soared by 63% YoY and by 11% QoQ
The stock's price to book (P/B) is 106% more than its 5-year quarterly average of 5.5 and 26% more than its last 4 quarters average of 9.0
Arcutis Biotherapeutics's equity has decreased by 37% YoY and by 9% QoQ
The company's revenue has surged by 100% YoY and by 8% QoQ
The price to sales (P/S) is 7% lower than the last 4 quarters average of 8.7
Efficiency
How efficient is Arcutis Biotherapeutics business performance
ARQT's ROS has soared by 71% YoY and by 12% QoQ
The ROE has soared by 59% YoY but it has contracted by 4.5% from the previous quarter
ARQT's return on assets is up by 46% year-on-year
The company's return on invested capital rose by 37% YoY but it fell by 4.6% QoQ
Dividends
What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARQT.
Financial health
How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 71% greater than its total liabilities
Arcutis Biotherapeutics's quick ratio has shrunk by 67% YoY and by 16% QoQ
The current ratio has plunged by 64% YoY and by 14% from the previous quarter
Arcutis Biotherapeutics's debt is 22% lower than its equity
Arcutis Biotherapeutics's debt has decreased by 46% YoY
Arcutis Biotherapeutics's equity has decreased by 37% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.